Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Investing Activities (2022 - 2024)

Historic Cash from Investing Activities for Addex Therapeutics (ADXN) over the last 3 years, with Q4 2024 value amounting to -$5320.8 billion.

  • Addex Therapeutics' Cash from Investing Activities fell 8382703.21% to -$5320.8 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $64.7 billion, marking a year-over-year increase of 8976828.61%. This contributed to the annual value of $5.3 million for FY2024, which is 6941078.14% up from last year.
  • As of Q4 2024, Addex Therapeutics' Cash from Investing Activities stood at -$5320.8 billion, which was down 8382703.21% from $5379.9 billion recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Cash from Investing Activities ranged from a high of $5379.9 billion in Q3 2024 and a low of -$5320.8 billion during Q4 2024
  • Its 3-year average for Cash from Investing Activities is $8.5 billion, with a median of -$2669.4 in 2023.
  • Per our database at Business Quant, Addex Therapeutics' Cash from Investing Activities surged by 6802351246492.38% in 2023 and then crashed by 8382703.21% in 2024.
  • Addex Therapeutics' Cash from Investing Activities (Quarter) stood at -$9.34 in 2022, then surged by 68023512464.92% to $6.4 billion in 2023, then tumbled by 83827.03% to -$5320.8 billion in 2024.
  • Its Cash from Investing Activities was -$5320.8 billion in Q4 2024, compared to $5379.9 billion in Q3 2024 and $6.4 billion in Q4 2023.